Efficacy and Safety of Ingenol Mebutate Gel 0.015% Compared to Diclofenac Sodium Gel 3% in Subjects With Actinic Keratoses on the Face or Scalp
Phase of Trial: Phase IV
Latest Information Update: 05 May 2017
At a glance
- Drugs Ingenol mebutate (Primary)
- Indications Actinic keratosis
- Focus Therapeutic Use
- Sponsors LEO Pharma
- 16 Sep 2016 Status changed from active, no longer recruiting to completed.
- 15 Jul 2016 Trial status has been completed in Germany (Global end date:2016-07-13).
- 11 May 2016 Trial status has been completed in Spain (Global end date:2016-06-10).